ClinicalTrials.gg
Not yet recruitingNCT07600151CONQUISTADORUpdated May 20, 2026

Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma

A Phase 1/2 interventional study of Etentamig and Isatuximab in Myeloma Multiple and Myeloma, sponsored by Universitätsklinikum Hamburg-Eppendorf. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
220
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing etentamig in Multiple Myeloma — 6 open to participants now, 10 under way, 3 of them phase 3. etentamig · Multiple Myeloma.

Planned enrollment
6th of 10
220 · median 235
Started
2026
with 2 others
Phase 1/2
3 of 10
2 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Universitätsklinikum Hamburg-Eppendorf

Among the 10 studies testing etentamig in Multiple Myeloma, this one is the 6th largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 1/2, and was the 9th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

6 of the 10 studies testing etentamig in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About etentamig

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing etentamig in Multiple Myeloma, or all of them as a file.
02

Study summary

This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.

03

Conditions studied

  • Myeloma Multiple
  • Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have confirmed diagnosis of symptomatic MM per IMWG criteria.
  • Participants must have High-risk myeloma according to IMS/IMWG CGS
  • Participants must be considered a candidate for high-dose chemotherapy and , as described in the protocol.
  • Participants must have as defined in the protocol. (ECOG) performance status of 0-2 (WHO=3 is allowed only if caused by MM and not by co-morbid conditions).
  • Participants must have clinical laboratory values within a prespecified range.

Exclusion criteria

Exclusion Criteria:

  • Known to the use of any IMP or axMP or required concomitant drugs or supportive treatment.
  • known systemic amyloidosis (except for AL amyloidosis of the skin or the bone marrow), POEMS syndrome, Waldenstrom's macroglobulinemia; primary plasma cell leukemia
  • Administration of systemic therapy for multiple myeloma except osteoprotective therapy. Emergency myeloma treatment with dexamethasone is allowed according to specifications in the protocol. It is allowed to include patients after 1 cycle of any anti-myeloma treatment within the specifications of the protocol
  • known central nervous system involvement by MM.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Dose level 1 (Phase I)

    First dose level of etentamig to be explored in combination with Isa-VRd

    Drug: Etentamig · Drug: Isatuximab · Drug: Bortezomib + Lenalidomide + Dexamethasone

  • Experimental
    Dose Level 2 (Phase I)

    Second dose level of etentamig to be explored in combination with Isa-VRd

    Drug: Etentamig · Drug: Isatuximab · Drug: Bortezomib + Lenalidomide + Dexamethasone

  • Experimental
    RP2D in Phase II

    RP2D of etentamig to be explored in combination with Isa-VRd

    Drug: Etentamig · Drug: Isatuximab · Drug: Bortezomib + Lenalidomide + Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability (Phase I)

    Number of dose-limiting toxicities (DLTs) in participants and rates of adverse events (AEs) of grade ≥2 and of severe AEs in participants

    Time frame: through induction treatment, on average 4 months

  2. MRD negativity (Phase II)

    MRD-negativity rate after 12 cycles (with a sensitivity of \<10-5)

    Time frame: through consolidation phase completion, an average of 1 year

  3. PFS

    Progression-free survival

    Time frame: up to 10 years

Secondary outcomes

  1. ORR

    Overall response rate

    Time frame: up to 10 years

  2. CR rate

    Complete Response Rate

    Time frame: up to 10 years

  3. VGPR Rate

    Very good partial response rate

    Time frame: up to 10 years

  4. DoR

    Duration of Response

    Time frame: up to 10 years

  5. TTR

    Time to response

    Time frame: up to 10 years

  6. PFS2

    Progression free survival 2

    Time frame: up to 10 years

  7. OS

    Overall survival

    Time frame: up to 10 years

  8. MRD negativity

    Minimal Residual Disease (MRD) Negativity Rate (10-5 to 10-6)

    Time frame: up to 10 years

  9. Sustained MRD

    Sustained MRD negativity rate (for a duration of 6-months, and multiples therof)

    Time frame: up to 10 years

  10. MRD-negative CR

    Rates of MRD-negative Complete Responses

    Time frame: up to 10 years

  11. Sustained MRD-negative CR

    Rate of Sustained MRD-negative Complete Response

    Time frame: up to 10 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2036, 117 months later.

Of 103 non-industry phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 94. This study's planned 117 months is above that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2026
First posted
May 20, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Sep 30, 2036
CompletionEst.
Dec 31, 2036
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07600151
Collaborators
AbbVie, Sanofi
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Sep 30, 2036 (estimated)
Completion
Dec 31, 2036 (estimated)
Last update
May 20, 2026

Study contacts

Katja Weisel
Contact
k.weisel@uke.de
+4940-7410-0
Lisa Leypoldt
Contact
l.leypoldt@uke.de
+4940-7410-0

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etentamig

Start the discussion